Vitamin B12 Deficiency Anemia
Clinical Snapshot
Vitamin B12 (cobalamin) deficiency impairs DNA synthesis in rapidly dividing cells, producing a megaloblastic, macrocytic anemia — but its clinically most important feature is that it can independently cause serious, sometimes irreversible neurologic complications (subacute combined degeneration of the spinal cord, peripheral neuropathy, cognitive change) that may appear before anemia develops or without any hematologic abnormality at all. Deficiency most often results from malabsorption — pernicious anemia (autoimmune loss of intrinsic factor) is the classic cause — but can also be purely dietary, particularly in strict vegans. A clinically important, still under-appreciated point: current evidence supports high-dose oral cyanocobalamin as an effective first-choice treatment for most patients with B12 deficiency, including many with malabsorption, not only those with a clearly dietary cause.[1]
Recognize the Condition
Two independent symptom domains
Hematologic manifestations
Fatigue, pallor, mild jaundice (from ineffective erythropoiesis/mild hemolysis), glossitis (a smooth, beefy-red tongue), and macrocytic anemia — sometimes progressing to pancytopenia in severe, longstanding deficiency.
Neurologic manifestations
Paresthesias, impaired vibration/proprioceptive sense, gait ataxia, and — in advanced cases — subacute combined degeneration of the spinal cord. Cognitive changes and psychiatric symptoms (irritability, depression, a dementia-like picture in older adults) can also occur. These neurologic findings can precede, or occur entirely without, anemia or macrocytosis — a high index of suspicion is warranted in an older adult with unexplained neurologic or cognitive change, even with a normal CBC.
Risk Factors
- Pernicious anemia — autoimmune destruction of gastric parietal cells causing loss of intrinsic factor, which is required for B12 absorption in the terminal ileum.
- Other causes of malabsorption: atrophic gastritis, prior gastric or ileal surgery (including bariatric surgery), Crohn disease or other terminal ileal disease, chronic pancreatitis, small intestinal bacterial overgrowth, and long-term metformin or acid-suppressing therapy (proton pump inhibitors, H2-receptor antagonists).
- Strict vegan diet, or a vegetarian diet without adequate supplementation — vitamin B12 occurs naturally only in animal-source foods.
- Older age — reduced gastric acid and reduced intrinsic factor production are more common with age.
- Nitrous oxide exposure/misuse, which inactivates vitamin B12.
- Fish tapeworm (Diphyllobothrium latum) infection — competes for dietary B12.
Red Flags & Refer
Escalate or refer for any of the following:
- Any neurologic symptoms attributable to B12 deficiency (paresthesias, gait/balance changes, cognitive change) — start parenteral B12 without delay rather than waiting to confirm the exact cause first; delayed treatment risks permanent neurologic deficits.
- Severe anemia with hemodynamic compromise.
- Confirmed pernicious anemia — consider referral for a one-time upper GI endoscopy given an increased long-term risk of gastric neoplasia (adenocarcinoma and carcinoid tumours) associated with the underlying autoimmune atrophic gastritis.
- B12 deficiency with low-normal or borderline serum levels in a patient with a clinical picture strongly suggestive of deficiency — do not rule out deficiency on a borderline level alone; further assessment (e.g., methylmalonic acid) or a treatment trial may be warranted.
Assessment & Diagnosis
History
- Diet (vegan/vegetarian pattern), prior GI surgery, known autoimmune disease (pernicious anemia clusters with other autoimmune conditions such as autoimmune thyroid disease and type 1 diabetes), alcohol use, and current medications (metformin, PPIs/H2-blockers, colchicine, anticonvulsants).
- Specifically ask about neurologic symptoms — numbness, tingling, balance problems, cognitive change — since these can be the only presenting feature.
Laboratory evaluation
- Serum cobalamin (B12) is the first-line test, but there is significant intra- and interindividual variation — patients with macrocytosis and a borderline B12 level need further assessment rather than being dismissed as normal. A level under 200 pmol/L is generally considered deficient or borderline deficient.
- Macrocytosis (MCV over 100 fL) with hypersegmented neutrophils on peripheral smear supports megaloblastic anemia, but a normal MCV does not exclude B12 deficiency, particularly when neurologic symptoms are the presenting feature or when concurrent iron deficiency masks the expected macrocytosis.
- Where diagnostic uncertainty remains, methylmalonic acid (elevated in true B12 deficiency, since B12 is a cofactor in its metabolism) can help clarify a borderline case.[2]
Treatment Targets
- Correct hemoglobin and macrocytosis to normal.
- Halt progression of, and maximize recovery from, any neurologic manifestations.
- Establish and maintain an adequate long-term maintenance regimen appropriate to the underlying cause.
Choose Initial Treatment
Neurologic symptoms present start parenteral (IM or SC) cyanocobalamin without delay, regardless of the suspected underlying cause — do not wait to confirm dietary versus malabsorptive etiology first.
No neurologic symptoms, and reliable daily adherence is realistic high-dose oral cyanocobalamin (1000-2000 mcg daily) is an effective first choice for most patients, including most patients with malabsorption or pernicious anemia — passive, intrinsic-factor-independent absorption of roughly 1-2% of a high oral dose is sufficient to meet requirements once the dose is high enough. This is a genuine, current, sometimes-surprising shift from the traditional teaching that malabsorptive B12 deficiency requires lifelong injections.[1][3]
Use parenteral therapy when adherence to daily oral dosing is uncertain, when oral access or cost is a genuine barrier, or per patient preference after discussing both options — daily oral adherence matters more for treatment success with the oral route than with injections, since a missed dose has a proportionally larger effect on oral maintenance.
Where dietary insufficiency is clearly the cause and no neurologic deficit is present, oral supplementation at a standard (non-high-dose) replacement level is adequate.
Non-Pharmacologic Treatment
- Restoring normal dietary B12 intake (meat, fish, poultry, eggs, dairy) may be sufficient for purely dietary deficiency without malabsorption.
- Counsel strict vegans on reliable long-term B12 supplementation regardless of whether current levels are deficient, given the absence of any dietary source.
- Address contributing factors where feasible — reducing excessive alcohol intake, and reviewing whether a chronic acid-suppressing medication or metformin is truly still needed.
Special Populations
Pregnancy
With the exception of strict vegans, some vegetarians, and patients with malabsorption (including pernicious anemia), B12 is generally maintained at sufficient levels during pregnancy without supplementation; serum B12 can decrease physiologically in pregnancy without indicating true deficiency. When supplementation is needed, dosing is the same as in nonpregnant adults. No teratogenic effects are associated with B12 supplementation.
Breastfeeding
Compatible — B12 passes into breast milk at concentrations approximating maternal blood levels, and normal-dose supplementation is not associated with adverse effects in the infant.
Older adults
B12 deficiency is common in this population, often from reduced gastric acid or reduced intrinsic factor; oral high-dose therapy is effective and avoids the burden of regular injections when adherence can be reasonably ensured. Older patients on diuretics for heart failure are at particular risk of treatment-induced hypokalemia and need close potassium monitoring at treatment initiation.
Renal impairment
No specific dose adjustment is required for B12 itself, but monitor potassium especially closely if renal impairment coexists with diuretic use.
Monitoring & Follow-Up
Expect a reticulocyte response within 3-4 days of starting effective therapy, with hemoglobin improving by about day 10 and full hematologic resolution within about 2 months. Check a baseline potassium level in at-risk patients (older adults on diuretics, severe anemia) before starting therapy, and monitor potassium closely in the first 48-72 hours, since rapid correction of severe megaloblastic anemia can cause a sudden, potentially profound drop in serum potassium as new blood cell production resumes.[2] Reassess reticulocyte count, B12, and folate levels between days 5 and 7. Neurologic recovery is slower — improvement can take 6 months or longer, and some severe or longstanding deficits may not fully resolve, which is why prompt treatment at the first neurologic symptom matters.
Common Errors to Avoid
- Waiting to confirm the exact cause of B12 deficiency before starting treatment in a patient with neurologic symptoms — start parenteral therapy without delay in that situation.
- Assuming a patient with malabsorption or pernicious anemia automatically needs lifelong injections — high-dose oral therapy is effective for most such patients if adherence is realistic.
- Treating B12 deficiency with folic acid alone, or failing to check B12 status before starting folic acid — see Folate Deficiency Anemia for why this is a distinct, important safety issue.
- Missing early hypokalemia when correcting severe megaloblastic anemia, particularly in an older patient on diuretics.
- Dismissing a borderline-normal B12 level in a patient with a strongly suggestive clinical picture.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation. Select any drug name to open its complete Pharmasist Drug Database page. Note: the Drug Database's "Hydroxocobalamin" entry (brand Cyanokit) is a high-dose IV cyanide-poisoning antidote, not a vitamin B12 replacement product, and is not referenced in this table.
Oral cyanocobalamin
Effective first choice for most patients, including most with malabsorption or pernicious anemia, provided daily adherence is realistic. Essentially nontoxic even at high doses — excess is renally excreted.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cyanocobalamin, oral | Induction/high-dose: 1000-2000 mcg PO daily until hematologic and biochemical normalization Maintenance: 1000 mcg PO daily, or a stepped-down schedule (1000 mcg daily, then weekly, then monthly) per current guideline-directed dosing Dietary deficiency without malabsorption or neurologic deficit: Standard (non-high-dose) oral replacement is adequate | Mild GI upset, headache; rare allergic reaction | Absorption reduced by anticonvulsants, colchicine, metformin, neomycin, PPIs/H2-blockers; high-dose vitamin C taken close in time may reduce bioavailability | Passive, intrinsic-factor-independent absorption at high dose makes this effective even in most malabsorptive states. |
Parenteral cyanocobalamin
Reserved for neurologic symptoms requiring the fastest possible correction, confirmed nonadherence to oral therapy, or inability to reliably attend follow-up monitoring on an oral regimen. Given IM or deep SC only — never IV.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cyanocobalamin, IM/SC | Induction, pernicious anemia/malabsorption: 100 mcg IM/SC daily for 1 week, then 200 mcg weekly until hemoglobin normalizes Induction, other B12 deficiency: 30 mcg IM/SC daily for 5-10 days Maintenance (lifelong for pernicious anemia): 100-1000 mcg IM/SC monthly | Rare anaphylaxis (consider an intradermal test dose in known-sensitive patients); peripheral vascular thrombosis, headache, nausea/vomiting, diarrhea; profound hypokalemia risk on rapid correction of severe anemia | Chloramphenicol reduces the blood-forming response; absorption-related interactions are not relevant to this route | Monitor potassium closely in the first 48 hours, particularly in older patients on diuretics or with severe baseline anemia. |
Evidence note: Drug inventory, dosing, adverse effects, and comments reflect current practice per the 2024 NICE NG239 guideline and the 2018 Cochrane review of oral versus intramuscular B12.[1][3]
References
- Vitamin B12 deficiency in over 16s: diagnosis and management — National Institute for Health and Care Excellence, NICE guideline NG239. NICE NG239, published 6 March 2024
- Guidelines for the diagnosis and treatment of cobalamin and folate disorders — British Journal of Haematology, British Committee for Standards in Haematology (Devalia V, Hamilton MS, Molloy AM). Br J Haematol 2014;166(4):496-513
- Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — Cochrane Database of Systematic Reviews (Wang H, Li L, Qin LL, et al.). Cochrane Database Syst Rev 2018;3(3):CD004655
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.